{"id":43852,"date":"2015-09-17T11:25:58","date_gmt":"2015-09-17T16:25:58","guid":{"rendered":"https:\/\/content.findlaw-admin.com\/ability-legal\/contracts\/uncategorized\/pricing-agreement-securities-issued-and-sold-pursuant-to.html"},"modified":"2015-09-17T11:25:58","modified_gmt":"2015-09-17T16:25:58","slug":"pricing-agreement-securities-issued-and-sold-pursuant-to","status":"publish","type":"corporate_contracts","link":"https:\/\/corporate.findlaw.com\/contracts\/securities\/pricing-agreement-securities-issued-and-sold-pursuant-to.html","title":{"rendered":"Pricing Agreement – Securities Issued and Sold Pursuant to Underwriting Agreement – UnitedHealth Group Inc."},"content":{"rendered":"

Pricing Agreement <\/u><\/em><\/p>\n

Merrill Lynch, Pierce, Fenner & Smith<\/p>\n

Incorporated<\/p>\n

50 Rockefeller Plaza<\/p>\n

NY1-050-12-1<\/p>\n

New York, New York 10020<\/p>\n

Barclays Capital Inc.<\/p>\n

745 Seventh Avenue<\/p>\n

New York, New York 10019<\/p>\n

Citigroup Global Markets Inc.<\/p>\n

388 Greenwich Street<\/p>\n

New York, New York 10013<\/p>\n

Credit Suisse Securities (USA) LLC<\/p>\n

One Madison Avenue<\/p>\n

New York, New York 10010<\/p>\n

As Representatives of the several Underwriters<\/p>\n

named in Schedule I to the applicable Pricing Agreement<\/p>\n

March 5, 2012<\/p>\n

Ladies and Gentlemen:<\/p>\n

UnitedHealth Group Incorporated, a Minnesota corporation (the “Company”),
\nproposes, subject to the terms and conditions stated herein and in the
\nUnderwriting Agreement, dated March 5, 2012 (the “Underwriting Agreement”),
\nbetween the Company on the one hand and Merrill Lynch, Pierce, Fenner &
\nSmith Incorporated, Barclays Capital Inc., Citigroup Global Markets Inc. and
\nCredit Suisse Securities (USA) LLC, on the other hand, to issue and sell to the
\nUnderwriters named in Schedule I hereto (the “Underwriters”) the Securities
\nspecified in Schedule II hereto (the “Designated Securities”). Each of the
\nprovisions of the Underwriting Agreement is incorporated herein by reference in
\nits entirety, and shall be deemed to be a part of this Agreement to the same
\nextent as if such provisions had been set forth in full herein; and each of the
\nrepresentations and warranties set forth therein shall be deemed to have been
\nmade at and as of the date of this Pricing Agreement, except that each
\nrepresentation and warranty which refers to the Prospectus in Section 3 of the
\nUnderwriting Agreement shall be deemed to be a representation or warranty as of
\nthe date of the Underwriting Agreement in relation to the Prospectus (as therein
\ndefined), and also a representation and warranty as of the date of this Pricing
\nAgreement in relation to the Prospectus as amended or supplemented relating to
\nthe Designated Securities which are the subject of this Pricing Agreement.
\nUnless otherwise defined herein, terms defined in the Underwriting Agreement are
\nused herein as therein defined. The Representatives designated to act on behalf
\nof the Representatives and on behalf of each of the Underwriters of the
\nDesignated Securities pursuant to Section 15 of the Underwriting Agreement and
\nthe address of the Representatives referred to in such Section 15 are set forth
\nat the end of Schedule II hereto.<\/p>\n

\n

An amendment to the Registration Statement, or a supplement to the
\nProspectus, as the case may be, relating to the Designated Securities, in the
\nform heretofore delivered to you is now proposed to be filed with the
\nCommission.<\/p>\n

At 4:05 p.m. (Eastern Time) on March 5, 2012 (the “Time of Sale<\/u>“), the
\nCompany had prepared the following information (collectively, the “Time of
\nSale Information<\/u>“): the Preliminary Prospectus dated March 5, 2012
\n(including the Base Prospectus dated February 14, 2011), and the “free-writing
\nprospectus” (as defined pursuant to Rule 405 under the Securities Act) listed on
\nSchedule III hereto, including a final term sheet in the form set forth in
\nSchedule IV.<\/p>\n

Subject to the terms and conditions set forth herein and in the Underwriting
\nAgreement incorporated herein by reference, the Company agrees to issue and sell
\nto each of the Underwriters, and each of the Underwriters agrees, severally and
\nnot jointly, to purchase from the Company, at the time and place and at the
\npurchase price to the Underwriters set forth in Schedule II hereto, the
\nprincipal amount of Designated Securities set forth opposite the name of such
\nUnderwriter in Schedule I hereto.<\/p>\n

If the foregoing is in accordance with your understanding, please sign and
\nreturn to us five counterparts hereof, and upon acceptance hereof by you, on
\nbehalf of each of the Underwriters, this letter and such acceptance hereof,
\nincluding the provisions of the Underwriting Agreement incorporated herein by
\nreference, shall constitute a binding agreement between each of the Underwriters
\nand the Company. It is understood that your acceptance of this letter on behalf
\nof each of the Underwriters is or will be pursuant to the authority set forth in
\na form of Agreement among Underwriters, the form of which shall be submitted to
\nthe Company for examination upon request, but without warranty on the part of
\nthe Representatives as to the authority of the signers thereof.<\/p>\n

[Signature Page to Follow] <\/strong><\/p>\n

\n\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Very truly yours,<\/p>\n

UNITEDHEALTH GROUP INCORPORATED<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/tr>\n
\n

By:<\/p>\n<\/td>\n

<\/td>\n\n

\/s\/ Paul Runice<\/p>\n<\/td>\n<\/tr>\n

\n

Name:<\/p>\n<\/td>\n

<\/td>\n\n

Paul Runice<\/p>\n<\/td>\n<\/tr>\n

\n

Title:<\/p>\n<\/td>\n

<\/td>\n\n

Assistant Treasurer<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

[Signature Page to Pricing Agreement<\/em>]<\/p>\n

\n\n\n\n\n\n\n\n
<\/td>\n<\/tr>\n
\n

MERRILL LYNCH, PIERCE, FENNER & SMITH<\/p>\n

MERRILL LYNCINCORPORATED<\/p>\n<\/td>\n<\/tr>\n

\n

BARCLAYS CAPITAL INC.<\/p>\n<\/td>\n<\/tr>\n

\n

CITIGROUP GLOBAL MARKETS INC.<\/p>\n<\/td>\n<\/tr>\n

\n

CREDIT SUISSE SECURITIES (USA) LLC<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Acting on behalf of themselves and the several Underwriters named in Schedule
\nI to the applicable Pricing Agreement<\/p>\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

By:<\/p>\n<\/td>\n

<\/td>\n\n

Merrill Lynch, Pierce, Fenner & Smith<\/p>\n

Merrill LyncIncorporated<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/tr>\n
\n

By:<\/p>\n<\/td>\n

<\/td>\n\n

\/s\/ Douglas A. Muller<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Douglas A. Muller<\/p>\n

Managing Director<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

[Signature Page to Pricing Agreement<\/em>]<\/p>\n

\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

By:<\/p>\n<\/td>\n

<\/td>\n\n

Barclays Capital Inc.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/tr>\n
\n

By:<\/p>\n<\/td>\n

<\/td>\n\n

\/s\/ Pamela Kendall<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Pamela Kendall<\/p>\n

Director<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

[Signature Page to Pricing Agreement<\/em>]<\/p>\n

\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

By:<\/p>\n<\/td>\n

<\/td>\n\n

Citigroup Global Markets Inc.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/tr>\n
\n

By:<\/p>\n<\/td>\n

<\/td>\n\n

\/s\/ Brian D. Bednarski<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Brian D. Bednarski<\/p>\n

Managing Director<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

[Signature Page to Pricing Agreement<\/em>]<\/p>\n

\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

By:<\/p>\n<\/td>\n

<\/td>\n\n

Credit Suisse Securities (USA) LLC<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/tr>\n
\n

By:<\/p>\n<\/td>\n

<\/td>\n\n

\/s\/ Christopher Murphy<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

Christopher Murphy<\/p>\n

Director<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

[Signature Page to Pricing Agreement<\/em>]<\/p>\n

\n

SCHEDULE I <\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Underwriter<\/strong><\/p>\n<\/td>\n

<\/td>\n\n

Principal Amount of
\n2022 Notes<\/strong><\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

Principal Amount of
\n2042 Notes<\/strong><\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Merrill Lynch, Pierce, Fenner & Smith<\/p>\n

Incorporated<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

120,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

80,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Barclays Capital Inc.<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

120,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

80,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Citigroup Global Markets Inc.<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

120,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

80,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Credit Suisse Securities (USA) LLC<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

120,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

80,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

BNY Mellon Capital Markets, LLC<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

12,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

8,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Deutsche Bank Securities Inc.<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

12,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

8,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Goldman, Sachs & Co.<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

12,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

8,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

J.P. Morgan Securities LLC<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

12,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

8,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

KeyBanc Capital Markets Inc.<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

12,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

8,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Morgan Stanley & Co. LLC<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

12,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

8,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

RBS Securities Inc.<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

12,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

8,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

UBS Securities LLC<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

12,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

8,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

U.S. Bancorp Investments, Inc.<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

12,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

8,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

Wells Fargo Securities, LLC<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

12,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

8,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Total<\/p>\n<\/td>\n

<\/td>\n\n

$<\/p>\n<\/td>\n

\n

600,000,000<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

$<\/p>\n<\/td>\n

\n

400,000,000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

4<\/p>\n

\n

SCHEDULE II <\/strong><\/p>\n

Title of Designated Securities<\/strong>:<\/p>\n

2.875% Notes Due March 15, 2022 (the “2022 Notes”)<\/p>\n

4.375% Notes Due March 15, 2042 (the “2042 Notes”)<\/p>\n

Aggregate principal amount<\/strong>:<\/p>\n

$600,000,000 for the 2022 Notes<\/p>\n

$400,000,000 for the 2042 Notes<\/p>\n

Price to Public<\/strong>:<\/p>\n

2022 Notes: 99.310% of the principal amount of the 2022 Notes, plus accrued
\ninterest, if any, from March 8, 2012.<\/p>\n

2042 Notes: 99.833% of the principal amount of the 2042 Notes, plus accrued
\ninterest, if any, from March 8, 2012.<\/p>\n

Purchase Price by Underwriters<\/strong>:<\/p>\n

2022 Notes: 98.860% of the principal amount of the 2022 Notes, plus accrued
\ninterest, if any, from March 8, 2012, if settlement occurs after that date.<\/p>\n

2042 Notes: 98.958% of the principal amount of the 2042 Notes, plus accrued
\ninterest, if any, from March 8, 2012, if settlement occurs after that date.<\/p>\n

Form of Designated Securities<\/strong>:<\/p>\n

Book-entry only form represented by one or more global securities deposited
\nwith The Depository Trust Company (“DTC”) or its designated custodian, to be
\nmade available for checking by the Representatives at least twenty-four hours
\nprior to the Time of Delivery at the office of DTC.<\/p>\n

Specified funds for payment of purchase price<\/strong>:<\/p>\n

Federal (same-day) funds<\/p>\n

Time of Delivery<\/strong>:<\/p>\n

10:30 a.m. (New York City time), March 8, 2012<\/p>\n

Indenture<\/strong>:<\/p>\n

Indenture, dated as of February 4, 2008, between the Company and U.S. Bank
\nNational Association, as Trustee.<\/p>\n

5<\/p>\n

\n

Maturity<\/strong>:<\/p>\n

2022 Notes: March 15, 2022<\/p>\n

2042 Notes: March 15, 2042<\/p>\n

Interest Rate<\/strong>:<\/p>\n

2022 Notes: 2.875%<\/p>\n

2042 Notes: 4.375%<\/p>\n

Interest Payment Dates<\/strong>:<\/p>\n

2022 Notes: March 15 and September 15, commencing September 15, 2012.<\/p>\n

2042 Notes: March 15 and September 15, commencing September 15, 2012.<\/p>\n

Redemption Provisions<\/strong>:<\/p>\n

The 2022 Notes and the 2042 Notes are redeemable by the Company, in whole or
\nin part and at any time on not less than 30 nor more than 60 days153 notice by
\nmail, at the redemption prices described in the Prospectus.<\/p>\n

Change of Control: <\/strong><\/p>\n

Upon the occurrence of a change of control triggering event, the Company will
\nbe required to offer to purchase from noteholders all of their notes at a price
\nequal to 101% of their principal amount, together with accrued and unpaid
\ninterest, if any, to the date of purchase.<\/p>\n

Sinking Fund Provisions<\/strong>:<\/p>\n

No sinking fund provisions.<\/p>\n

Defeasance Provisions<\/strong>:<\/p>\n

Defeasance provisions set forth in Article IX of the Indenture shall apply to
\nthe Designated Securities.<\/p>\n

Closing Date, Time and Location<\/strong>:<\/p>\n

March 8, 2012, at 9:00 a.m., New York City time, at the offices of Simpson
\nThacher & Bartlett LLP, 425 Lexington Avenue, New York, New York 10017.<\/p>\n

Names and Addresses of Representatives<\/strong>:<\/p>\n

As to the 2022 Notes and the 2042 Notes (and designated to act on behalf of
\nthe other Underwriters or other Representatives):<\/p>\n

Merrill Lynch, Pierce, Fenner & Smith Incorporated<\/p>\n

50 Rockefeller Plaza<\/p>\n

NY1-050-12-1<\/p>\n

New York, New York 10020<\/p>\n

Attn: High Grade Legal\/Transaction Management<\/p>\n

6<\/p>\n

\n

Barclays Capital Inc.<\/p>\n

745 Seventh Avenue<\/p>\n

New York, New York 10019<\/p>\n

Citigroup Global Markets Inc.<\/p>\n

388 Greenwich Street<\/p>\n

New York, New York 10013<\/p>\n

Credit Suisse Securities (USA) LLC<\/p>\n

One Madison Avenue<\/p>\n

New York, New York 10010<\/p>\n

Attn: Prospectus Department<\/p>\n

7<\/p>\n

\n

SCHEDULE III <\/strong><\/p>\n

List of each Issuer Free Writing Prospectus to be included in the
\nTime of Sale Information: <\/strong><\/p>\n\n\n\n
\n<\/td>\n<\/td>\n\n

Final term sheet, dated March 5, 2012, relating to the 2022 Notes and the
\n2042 Notes, as filed pursuant to Rule 433 under the Securities Act.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

8<\/p>\n

\n

Issuer Free Writing Prospectus<\/p>\n

Filed Pursuant to Rule 433<\/p>\n

Registration Statement No. 333-172235<\/p>\n

March 5, 2012<\/p>\n

SCHEDULE IV <\/strong><\/p>\n

UNITEDHEALTH GROUP INCORPORATED<\/p>\n

$600,000,000 2.875% NOTES DUE MARCH 15, 2022<\/p>\n

$400,000,000 4.375% NOTES DUE MARCH 15, 2042<\/p>\n

FINAL TERM SHEET <\/u><\/p>\n

Dated March 5, 2012<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Issuer:<\/p>\n<\/td>\n

<\/td>\n\n

UnitedHealth Group Incorporated<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Ratings*:<\/p>\n<\/td>\n

<\/td>\n\n

[Intentionally omitted]<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Note Type:<\/p>\n<\/td>\n

<\/td>\n\n

SEC Registered (No. 333-172235)<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Trade Date:<\/p>\n<\/td>\n

<\/td>\n\n

March 5, 2012<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Settlement Date (T+ 3):<\/p>\n<\/td>\n

<\/td>\n\n

March 8, 2012<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Title of Securities:<\/p>\n<\/td>\n

<\/td>\n\n

2.875% Notes Due March 15, 2022 (“2022 Notes”)<\/p>\n

4.375% Notes Due March 15, 2042 (“2042 Notes”)<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Maturity Date:<\/p>\n<\/td>\n

<\/td>\n\n

March 15, 2022 (2022 Notes)<\/p>\n

March 15, 2042 (2042 Notes)<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Principal Amount Offered:<\/p>\n<\/td>\n

<\/td>\n\n

$600,000,000 (2022 Notes)<\/p>\n

$400,000,000 (2042 Notes)<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Price to Public (Issue Price):<\/p>\n<\/td>\n

<\/td>\n\n

99.310% (2022 Notes)<\/p>\n

99.833% (2042 Notes)<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Interest Rate:<\/p>\n<\/td>\n

<\/td>\n\n

2.875% (2022 Notes)<\/p>\n

4.375% (2042 Notes)<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Interest Payment Dates:<\/p>\n<\/td>\n

<\/td>\n\n

March 15 and September 15, commencing September 15, 2012<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Benchmark:<\/p>\n<\/td>\n

<\/td>\n\n

2.000% due 02\/15\/2022 (2022 Notes)<\/p>\n

3.125% due 11\/15\/2041 (2042 Notes)<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Benchmark Yield:<\/p>\n<\/td>\n

<\/td>\n\n

2.005% (2022 Notes)<\/p>\n

3.135% (2042 Notes)<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

Spread to Benchmark:<\/p>\n<\/td>\n

<\/td>\n\n

95 basis points (2022 Notes)<\/p>\n

125 basis points (2042 Notes)<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

9<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/tr>\n
\n

Re-offer Yield:<\/p>\n<\/td>\n

<\/td>\n\n

2.955% (2022 Notes)<\/p>\n

4.385% (2042 Notes)<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/tr>\n
\n

Optional Redemption Provisions:<\/p>\n<\/td>\n

<\/td>\n\n

Prior to December 15, 2021, make-whole call at any time at a discount rate of
\nU.S. Treasury plus 15 basis points; par call on and after December 15, 2021.
\n(2022 Notes)<\/p>\n

Prior to September 15, 2041, make-whole call at any time at a discount rate
\nof U.S. Treasury plus 20 basis points; par call on and after September 15, 2041.
\n(2042 Notes)<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/tr>\n
\n

Change of Control:<\/p>\n<\/td>\n

<\/td>\n\n

If a change of control triggering event occurs, the Issuer will be required
\nto make an offer to repurchase the Notes at a price equal to 101% of the
\nprincipal amount of the Notes, plus accrued and unpaid interest to the date of
\nrepurchase.<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/tr>\n
\n

CUSIP:<\/p>\n<\/td>\n

<\/td>\n\n

91324PBV3 (2022 Notes)<\/p>\n

91324PBW1 (2042 Notes)<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/tr>\n
\n

ISIN:<\/p>\n<\/td>\n

<\/td>\n\n

US91324PBV31 (2022 Notes)<\/p>\n

US91324PBW14 (2042 Notes)<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/tr>\n
\n

Joint Book-Runners:<\/p>\n<\/td>\n

<\/td>\n\n

Merrill Lynch, Pierce, Fenner & Smith Incorporated<\/p>\n

Barclays Capital Inc.<\/p>\n

Citigroup Global Markets Inc.<\/p>\n

Credit Suisse Securities (USA) LLC<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/tr>\n
\n

Co-Managers:<\/p>\n<\/td>\n

<\/td>\n\n

BNY Mellon Capital Markets, LLC<\/p>\n

Deutsche Bank Securities Inc.<\/p>\n

Goldman, Sachs & Co.<\/p>\n

J.P. Morgan Securities LLC<\/p>\n

KeyBanc Capital Markets Inc.<\/p>\n

Morgan Stanley & Co. LLC<\/p>\n

RBS Securities Inc.<\/p>\n

UBS Securities LLC<\/p>\n

U.S. Bancorp Investments, Inc.<\/p>\n

Wells Fargo Securities, LLC<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/p>\n\n\n\n
\n

*<\/p>\n<\/td>\n

\n

Note: A securities rating is not a recommendation to buy, sell or hold
\nsecurities and may be subject to revision, suspension or withdrawal at any time.\n<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The issuer has filed a registration statement (including a
\nprospectus) with the SEC for the offering to which this communication relates.
\nBefore you invest, you should read the prospectus in that registration statement
\nand other documents the issuer has filed with the SEC for more complete
\ninformation about the issuer and this offering. You may get these documents for
\nfree by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the
\nissuer, any underwriter or any dealer participating in the offering will arrange
\nto send you the prospectus if you request it by <\/strong><\/p>\n

10<\/p>\n

\n

calling Merrill Lynch, Pierce, Fenner & Smith Incorporated at
\n1-800-294-1322, Barclays Capital Inc. at 1-888-603-5847, Citigroup Global
\nMarkets Inc. at 1-877-858-5407 or Credit Suisse Securities (USA) LLC at
\n1-800-221-1037. <\/strong><\/p>\n

Any disclaimer or other notice that may appear below is not
\napplicable to this communication and should be disregarded. Such disclaimer or
\nnotice was automatically generated as a result of this communication being sent
\nby Bloomberg or another email system. <\/strong><\/p>\n

11<\/p><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"_stopmodifiedupdate":true,"_modified_date":"","_cloudinary_featured_overwrite":false},"corporate_contracts_companies":[9178],"corporate_contracts_industries":[9440],"corporate_contracts_types":[9629,9634],"class_list":["post-43852","corporate_contracts","type-corporate_contracts","status-publish","hentry","corporate_contracts_companies-unitedhealth-group-inc","corporate_contracts_industries-health__plans","corporate_contracts_types-securities","corporate_contracts_types-securities__underwriting"],"acf":[],"_links":{"self":[{"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts\/43852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts"}],"about":[{"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/types\/corporate_contracts"}],"wp:attachment":[{"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/media?parent=43852"}],"wp:term":[{"taxonomy":"corporate_contracts_companies","embeddable":true,"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts_companies?post=43852"},{"taxonomy":"corporate_contracts_industries","embeddable":true,"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts_industries?post=43852"},{"taxonomy":"corporate_contracts_types","embeddable":true,"href":"https:\/\/corporate.findlaw.com\/legal-api\/wp-json\/wp\/v2\/corporate_contracts_types?post=43852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}